Relation of SFRP promoter methylation with clinicopathologic variables
| Variables . | SFRP-M (n = 23) . | No SFRP-M (n = 36) . | P . | SFRP1-M (n = 20) . | SFRP1-U (n = 39) . | P . | SFRP2-M (n = 10) . | SFRP2-U (n = 49) . | P . |
|---|---|---|---|---|---|---|---|---|---|
| Median age, y | 12 | 3.5 | .0001 | 12.5 | 7 | .001 | 14 | 8 | .004 |
| Sex, n (% males) | 17 (74) | 16 (44) | .034 | 15 (75) | 18 (46) | .052 | 8 (80) | 25 (51) | .161 |
| Hemoglobin level, g/dL, median | 7.6 | 7.8 | .692 | 7.5 | 7.9 | .762 | 8.2 | 7.6 | .154 |
| Platelet count, 109/L, median | 45 | 58 | .110 | 43 | 56.5 | .081 | 43 | 54 | .283 |
| WBC count, 109/L, median | 25.9 | 15.4 | .423 | 20 | 16.4 | .359 | 28.2 | 14.3 | .765 |
| FAB type* | .0005 | .001 | .044 | ||||||
| M0/M1/M2, n | 17 | 7 | 15 | 9 | 9 | 15 | |||
| M3, n | 0 | 7 | 0 | 7 | 0 | 7 | |||
| M4, n | 4 | 3 | 4 | 3 | 1 | 6 | |||
| M5, n | 2 | 8 | 1 | 9 | 0 | 10 | |||
| M6, n | 0 | 1 | 0 | 1 | 0 | 1 | |||
| M7, n | 0 | 9 | 0 | 9 | 0 | 9 | |||
| Unclassified, n | 0 | 1 | 0 | 1 | 0 | 1 | |||
| Chromosome aberration | |||||||||
| t(8;21), n (%) | 8 (35) | 2 (6) | .009 | 8 (40) | 2 (5) | .002 | 0 (0) | 10 (20) | .186 |
| inv(16), n (%) | 2 (9) | 4 (11) | .999 | 2 (10) | 4 (10) | .999 | 1 (10) | 5 (10) | .999 |
| t(15;17), n (%) | 0 (0) | 7 (19) | .036 | 0 (0) | 7 (18) | .083 | 0 (0) | 7 (14) | .590 |
| 11q23, n (%) | 0 (0) | 6 (17) | .072 | 0 (0) | 6 (15) | .087 | 0 (0) | 6 (12) | .577 |
| Normal karyotype, n (%) | 10 (43) | 5 (14) | .015 | 7 (35) | 8 (21) | .344 | 7 (70) | 8 (16) | .002 |
| Genetic mutations | |||||||||
| FLT3, n (%)† | 3 (13) | 7 (19) | .726 | 2 (10) | 8 (21) | .469 | 0 (0) | 10 (20) | .186 |
| KIT, n (%) | 3 (13) | 1 (3) | .289 | 3 (15) | 1 (3) | 0.108 | 1 (10) | 3 (6) | .535 |
| NPM1, n (%) | 0 (0) | 2 (6) | .516 | 0 (0) | 2 (5) | 0.544 | 0 (0) | 2 (4) | .999 |
| CEBPA, n (%)‡ | 3 (13) | 0 (0) | .055 | 3 (15) | 0 (0) | 0.035 | 3 (30) | 0 (0) | .004 |
| Variables . | SFRP-M (n = 23) . | No SFRP-M (n = 36) . | P . | SFRP1-M (n = 20) . | SFRP1-U (n = 39) . | P . | SFRP2-M (n = 10) . | SFRP2-U (n = 49) . | P . |
|---|---|---|---|---|---|---|---|---|---|
| Median age, y | 12 | 3.5 | .0001 | 12.5 | 7 | .001 | 14 | 8 | .004 |
| Sex, n (% males) | 17 (74) | 16 (44) | .034 | 15 (75) | 18 (46) | .052 | 8 (80) | 25 (51) | .161 |
| Hemoglobin level, g/dL, median | 7.6 | 7.8 | .692 | 7.5 | 7.9 | .762 | 8.2 | 7.6 | .154 |
| Platelet count, 109/L, median | 45 | 58 | .110 | 43 | 56.5 | .081 | 43 | 54 | .283 |
| WBC count, 109/L, median | 25.9 | 15.4 | .423 | 20 | 16.4 | .359 | 28.2 | 14.3 | .765 |
| FAB type* | .0005 | .001 | .044 | ||||||
| M0/M1/M2, n | 17 | 7 | 15 | 9 | 9 | 15 | |||
| M3, n | 0 | 7 | 0 | 7 | 0 | 7 | |||
| M4, n | 4 | 3 | 4 | 3 | 1 | 6 | |||
| M5, n | 2 | 8 | 1 | 9 | 0 | 10 | |||
| M6, n | 0 | 1 | 0 | 1 | 0 | 1 | |||
| M7, n | 0 | 9 | 0 | 9 | 0 | 9 | |||
| Unclassified, n | 0 | 1 | 0 | 1 | 0 | 1 | |||
| Chromosome aberration | |||||||||
| t(8;21), n (%) | 8 (35) | 2 (6) | .009 | 8 (40) | 2 (5) | .002 | 0 (0) | 10 (20) | .186 |
| inv(16), n (%) | 2 (9) | 4 (11) | .999 | 2 (10) | 4 (10) | .999 | 1 (10) | 5 (10) | .999 |
| t(15;17), n (%) | 0 (0) | 7 (19) | .036 | 0 (0) | 7 (18) | .083 | 0 (0) | 7 (14) | .590 |
| 11q23, n (%) | 0 (0) | 6 (17) | .072 | 0 (0) | 6 (15) | .087 | 0 (0) | 6 (12) | .577 |
| Normal karyotype, n (%) | 10 (43) | 5 (14) | .015 | 7 (35) | 8 (21) | .344 | 7 (70) | 8 (16) | .002 |
| Genetic mutations | |||||||||
| FLT3, n (%)† | 3 (13) | 7 (19) | .726 | 2 (10) | 8 (21) | .469 | 0 (0) | 10 (20) | .186 |
| KIT, n (%) | 3 (13) | 1 (3) | .289 | 3 (15) | 1 (3) | 0.108 | 1 (10) | 3 (6) | .535 |
| NPM1, n (%) | 0 (0) | 2 (6) | .516 | 0 (0) | 2 (5) | 0.544 | 0 (0) | 2 (4) | .999 |
| CEBPA, n (%)‡ | 3 (13) | 0 (0) | .055 | 3 (15) | 0 (0) | 0.035 | 3 (30) | 0 (0) | .004 |
M indicates methylation; U, unmethylation; WBC, white blood cell; NPM1, nucleophosmin; and CEBPA, CCAAT/enhancer binding protein α.
P for FAB type association were calculated by χ2 test.
Nine patients with in-frame internal tandem duplications and 1 patient with D835H.
The incidence refers to double mutations.